Published in J Clin Oncol on July 01, 1999
Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol (2008) 2.04
Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol (2010) 1.52
Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults. Clin Res Cardiol (2008) 1.13
Anthracycline-associated cardiotoxicity in survivors of childhood cancer. Pediatr Cardiol (2011) 1.12
Mito-tempol and dexrazoxane exhibit cardioprotective and chemotherapeutic effects through specific protein oxidation and autophagy in a syngeneic breast tumor preclinical model. PLoS One (2013) 0.91
Cardiotoxicity in childhood cancer survivors: strategies for prevention and management. Future Cardiol (2012) 0.91
Serum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patients. Front Oncol (2014) 0.91
Cardiac biomarkers in HIV-exposed uninfected children. AIDS (2013) 0.88
Cardiovascular effects in childhood cancer survivors treated with anthracyclines. Cardiol Res Pract (2011) 0.86
Noninvasive diagnosis of chemotherapy related cardiotoxicity. Curr Cardiol Rev (2011) 0.86
Myocardial performance index and biochemical markers for early detection of doxorubicin-induced cardiotoxicity in children with acute lymphoblastic leukaemia. Int J Clin Oncol (2012) 0.85
Enhanced antitumor efficacy and reduced systemic toxicity of sulfatide-containing nanoliposomal doxorubicin in a xenograft model of colorectal cancer. PLoS One (2012) 0.82
Prognostic role of troponin and natriuretic peptides as biomarkers for deterioration of left ventricular ejection fraction after chemotherapy. Arch Med Sci (2013) 0.81
Serial measurements of cardiac biomarkers in patients after allogeneic hematopoietic stem cell transplantation. J Exp Clin Cancer Res (2012) 0.80
Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity. Clin Biochem (2014) 0.80
Cardiomyopathy Caused by Antineoplastic Therapies. Curr Treat Options Cardiovasc Med (2001) 0.79
Utilizing cardiac biomarkers to detect and prevent chemotherapy-induced cardiomyopathy. Curr Heart Fail Rep (2015) 0.78
MicroRNAs as early toxicity signatures of doxorubicin in human-induced pluripotent stem cell-derived cardiomyocytes. Arch Toxicol (2016) 0.78
Improved efficacy and reduced toxicity of doxorubicin encapsulated in sulfatide-containing nanoliposome in a glioma model. PLoS One (2014) 0.77
Cardiac toxicity assessment in locally advanced breast cancer treated neoadjuvantly with doxorubicin/paclitaxel regimen. Support Care Cancer (2005) 0.76
Risks and diagnosis of coronary artery disease in Hodgkin lymphoma survivors. World J Cardiol (2014) 0.76
Pharmacokinetic-pharmacodynamic modelling of acute N-terminal pro B-type natriuretic peptide after doxorubicin infusion in breast cancer. Br J Clin Pharmacol (2016) 0.75
How could we solve the diagnostic dilemma of doxorubicin toxicity in high-risk patients? J Natl Med Assoc (2004) 0.75
Can we find a good biochemical marker of early cardiotoxicity in children treated with haematopoietic stem cell transplantation? Contemp Oncol (Pozn) (2016) 0.75
The utility of serum biomarkers to detect myocardial alterations induced by Imatinib in rats. Pharmacol Res Perspect (2014) 0.75
Decitabine induced transient cardiomyopathy: a case report. Clin Med Insights Oncol (2012) 0.75
Early change in left atrial function in patients treated with anthracyclines assessed by real-time three-dimensional echocardiography. Sci Rep (2016) 0.75
Creating a Biomarker Panel for Early Detection of Chemotherapy Related Cardiac Dysfunction in Breast Cancer Patients. J Clin Exp Cardiolog (2017) 0.75
Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res (1997) 665.31
The sequence of the human genome. Science (2001) 101.55
Comparative genomics of the eukaryotes. Science (2000) 26.62
A Toll-like receptor recognizes bacterial DNA. Nature (2000) 26.34
Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol (2001) 18.80
Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity (1998) 18.12
C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med (2000) 18.04
Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity (1999) 17.40
Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol (1999) 16.86
C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA (2001) 15.85
Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med (2001) 12.38
Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity (1999) 11.64
Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J (1998) 9.36
Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation (2000) 8.17
Requirement for generation of H2O2 for platelet-derived growth factor signal transduction. Science (1995) 8.17
The vasorelaxant effect of H(2)S as a novel endogenous gaseous K(ATP) channel opener. EMBO J (2001) 7.97
The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation. Cell Death Differ (2007) 7.74
Toll-like receptors control activation of adaptive immune responses. Nat Immunol (2001) 7.54
Engineering the provitamin A (beta-carotene) biosynthetic pathway into (carotenoid-free) rice endosperm. Science (2000) 7.53
Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med (2001) 7.51
Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography. Am J Respir Crit Care Med (1997) 7.12
Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia (2006) 6.31
Inflammatory and immune processes in the human lung in health and disease: evaluation by bronchoalveolar lavage. Am J Pathol (1979) 5.94
A potential vulnerability locus for schizophrenia on chromosome 6p24-22: evidence for genetic heterogeneity. Nat Genet (1995) 5.87
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet (2001) 5.80
Association between dietary patterns and plasma biomarkers of obesity and cardiovascular disease risk. Am J Clin Nutr (2001) 5.67
The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nat Genet (1997) 5.55
Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA (2001) 5.54
Sites of specific B cell activation in primary and secondary responses to T cell-dependent and T cell-independent antigens. Eur J Immunol (1991) 5.38
The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem (1995) 5.36
Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int Immunol (2001) 5.36
ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis. EMBO Rep (2001) 5.32
A kinase-cyclin pair in the RNA polymerase II holoenzyme. Nature (1995) 4.93
One drug for epilepsy. Br Med J (1978) 4.87
Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology (2001) 4.84
NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med (1982) 4.70
HCFA's racial and ethnic data: current accuracy and recent improvements. Health Care Financ Rev (2000) 4.67
Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev (2001) 4.47
Ras proteins induce senescence by altering the intracellular levels of reactive oxygen species. J Biol Chem (1999) 4.38
Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11). Am J Med (1977) 4.34
Endovascular stent-graft placement for the treatment of acute aortic dissection. N Engl J Med (1999) 4.33
One drug (phenytoin) in the treatment of epilepsy. Lancet (1976) 4.32
CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology (2007) 4.24
Sequence specificity in the dimerization of transmembrane alpha-helices. Biochemistry (1992) 4.19
An essential role in liver development for transcription factor XBP-1. Genes Dev (2000) 4.17
Comparative analysis of 1196 orthologous mouse and human full-length mRNA and protein sequences. Genome Res (1996) 4.11
Cutting edge: endotoxin tolerance in mouse peritoneal macrophages correlates with down-regulation of surface toll-like receptor 4 expression. J Immunol (2000) 4.10
The nuclear receptor CAR mediates specific xenobiotic induction of drug metabolism. Nature (2000) 4.00
ASK1 is essential for JNK/SAPK activation by TRAF2. Mol Cell (1998) 3.98
Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation (1999) 3.90
Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci (2001) 3.85
Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther (2003) 3.85
Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem (1998) 3.77
Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem (1994) 3.73
The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia (2008) 3.69
Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation (2000) 3.66
Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene (2009) 3.64
Progression of kidney dysfunction in the community-dwelling elderly. Kidney Int (2006) 3.64
A local alignment tool for very long DNA sequences. Comput Appl Biosci (1995) 3.58
IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production. J Immunol (1998) 3.56
Pig cloning by microinjection of fetal fibroblast nuclei. Science (2000) 3.51
Nitric oxide-induced apoptosis in pancreatic beta cells is mediated by the endoplasmic reticulum stress pathway. Proc Natl Acad Sci U S A (2001) 3.49
Pten regulates neuronal soma size: a mouse model of Lhermitte-Duclos disease. Nat Genet (2001) 3.48
The beta2-adrenergic receptor/betaarrestin complex recruits the clathrin adaptor AP-2 during endocytosis. Proc Natl Acad Sci U S A (1999) 3.43
The knockout of miR-143 and -145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease. Cell Death Differ (2009) 3.43
Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med (1996) 3.40
Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet (1999) 3.39
Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomised controlled trial. Lancet (2005) 3.38
Nuclear receptor corepressors partner with class II histone deacetylases in a Sin3-independent repression pathway. Genes Dev (2000) 3.38
Mutation in the silencing gene SIR4 can delay aging in S. cerevisiae. Cell (1995) 3.37
Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med (1995) 3.32
CCR6 mediates dendritic cell localization, lymphocyte homeostasis, and immune responses in mucosal tissue. Immunity (2000) 3.28
Roles of bone morphogenetic protein type I receptors and Smad proteins in osteoblast and chondroblast differentiation. Mol Biol Cell (1999) 3.27
Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol (2000) 3.24
Influenza virus hemagglutinin and neuraminidase cytoplasmic tails control particle shape. EMBO J (1997) 3.23
Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J (1999) 3.19
Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation (1998) 3.19
BCL-6 protein is expressed in germinal-center B cells. Blood (1995) 3.18
Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2. Clin Chem (2001) 3.17
The EGF-CFC protein one-eyed pinhead is essential for nodal signaling. Cell (1999) 3.15
Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol (1998) 3.13
Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem (2001) 3.12
A beta-arrestin/green fluorescent protein biosensor for detecting G protein-coupled receptor activation. J Biol Chem (1997) 3.12
Cutting edge: cell surface expression and lipopolysaccharide signaling via the toll-like receptor 4-MD-2 complex on mouse peritoneal macrophages. J Immunol (2000) 3.10
Interstitial lung disease: current concepts of pathogenesis, staging and therapy. Am J Med (1981) 3.08
Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med (1998) 3.05
CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J Exp Med (2001) 3.05
Activation of the Wnt signaling pathway: a molecular mechanism for lithium action. Dev Biol (1997) 3.03
Applications of network BLAST server. Methods Enzymol (1996) 3.03
Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of Stat3. Genes Dev (1999) 2.91
Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res (1999) 2.87
Lethal mutagenesis of HIV with mutagenic nucleoside analogs. Proc Natl Acad Sci U S A (1999) 2.85
IKK-i, a novel lipopolysaccharide-inducible kinase that is related to IkappaB kinases. Int Immunol (1999) 2.84